lidoflazine has been researched along with Myocarditis in 1 studies
Lidoflazine: Coronary vasodilator with some antiarrhythmic action.
Myocarditis: Inflammatory processes of the muscular walls of the heart (MYOCARDIUM) which result in injury to the cardiac muscle cells (MYOCYTES, CARDIAC). Manifestations range from subclinical to sudden death (DEATH, SUDDEN). Myocarditis in association with cardiac dysfunction is classified as inflammatory CARDIOMYOPATHY usually caused by INFECTION, autoimmune diseases, or responses to toxic substances. Myocarditis is also a common cause of DILATED CARDIOMYOPATHY and other cardiomyopathies.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lehmann, HU | 1 |
| Hochrein, H | 1 |
1 trial available for lidoflazine and Myocarditis
| Article | Year |
|---|---|
[Antiarrhythmic properties of lidoflazine in the therapy of auricular fibrillation and flutter (clinical studies of 26 patients)].
Topics: Aged; Arteriosclerosis; Atrial Fibrillation; Atrial Flutter; Clinical Trials as Topic; Electrocardio | 1975 |